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Summary Microvessel density of benign, borderline and malignant ovarian tumours was studied immunohistochemically using antibodies
to the endothelial cell markers CD31, CD34 and factor VIII-related antigen. Microvessel density was compared in tumours of different
histological subtype, stage and patient outcome. CD31-immunostained sections were examined and regions of high and average microvessel
density were selected. Identical regions were located on CD34- and factor Vill-related antigen-immunostained serial sections and microvessel
counts obtained and converted to vessels mm-2. CD31 and CD34 immunostaining revealed increased microvessel density in both the high and
average vessel density regions of mucinous (222.4 ± 24.8; 79.9 + 8.5) compared with serous (105.4 + 20.7; 33.3 ± 6.8) and benign (84.4 +
19.4; 20.4 + 4.4) tumours (P < 0.001). CD31 and CD34 immunostaining also revealed increased microvessel density in early-stage mucinous
tumours (234.6 ± 28.2; 87.8 + 9.2) compared with that observed in both early- (72.8 + 15; 12.9 ± 2.4) and late- (115.6 ± 26.5; 29.8 + 8.5) stage
serous tumours (P < 0.001). No differences in microvessel density in samples from patients with differing outcomes were observed (P > 0.05).
Reduced factor VIII-related antigen compared with CD31 and CD34 immunostaining was observed in both borderline and malignant mucinous
and serous tumours (P < 0.02) but not in benign tumours (P > 0.05). Our results contradict the putative association between increased
microvessel density and poor prognosis and suggest that the level and control of angiogenesis may differ between ovarian tumour types.
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Epithelial ovarian cancer is a common gynaecological malig-
nancy. Most patients are diagnosed in the advanced stages of the
disease and 5-year survival rates are, at approximately 20%, quite
low (Kristensen and Trope, 1997). Angiogenesis, or the growth of
new blood vessels, is essential for the development, growth and
spread of solid tumours (Folkman, 1985). Measurements of
microvessel density (MVD) are often used to indicate tumour
angiogenesis, and two of three recent studies of MVD in ovarian
carcinoma have demonstrated an association between increased
MVD and reduced patient survival (Hollingsworth et al, 1995; van
Diest et al, 1995; Gasparini et al, 1995).
Most ovarian neoplasms arise from the epithelium of the ovary
and may be benign, malignant orborderline (low malignant potential
tumours). Epithelial ovarian tumours are staged (I-IV) according to
tumour spread, and a number of histological subtypes exist,
including serous, mucinous, endometrioid, clearcell, transitional cell
and mixed epithelial (Kristensen and Trope, 1997). In this study we
quantified MVD in benign tumours and in borderline and malignant
tumours of the serous and mucinous types. Malignant serous
tumours are generally diagnosed at later stages and survival rates are
low. Mucinous tumours are generally early-stage, borderline tumours
and patients diagnosed with these tumours have a more favourable
outcome (Kristensen and Trope, 1997). The first aim of this study
was to compare microvessel density in benign, mucinous and serous
tumours and to relate this to the prognosis ofthese tumourtypes.
An association between elevated MVD and patient prognosis has
been demonstrated in many tumour types, although other studies
have failed to repeat these observations (reviewed in Weidner, 1995).
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Heterogeneity ofthe tumour vasculature is well recognized (Weidner
et al, 1991; Visscher et al, 1994) and mostprognostic studies evaluate
MVD in regions ofhigh microvessel density orareas termed vascular
'hotspots'. These regions are not only thought to represent regions of
ongoing tumour angiogenesis but also to be the site of tumour cell
entry into the circulation (Rak et al, 1995a; Weidner, 1995).
However, rather than spreading via the vasculature, ovarian tumours
generally spread by peritoneal dissemination (Kristensen and Trope,
1997) and tumour angiogenesis is unlikely to play a role in this type
of spread. The growth of the primary ovarian tumour and its peri-
toneal metastases is dependent on continued blood vessel growth
(Sheid, 1992), and regions other than vascular 'hotspots' may
contribute to this growth. Thus, the second aim of this study was to
compare MVD in both high vessel density (HVD) and average vessel
density (AVD) regions ofovarian tumours ofdiffering prognosis.
A variety of endothelial cell markers can be used to highlight
tumour blood vessels immunohistochemically. The most commonly
used antibodies include those to factor VIII-related antigen, CD31
and CD34. Factor VIII forms part of the von Willebrand factor
complex and plays a role in the coagulation process (Fay, 1993).
CD31, also known as platelet-endothelial cell adhesion molecule, is a
transmembrane glycoprotein involved in cell-cell adhesion
(DeLisser et al, 1994) and CD34 is a surface glycoprotein of
unknown function (Krause et al, 1996). The relative abilities ofthese
antibodies to highlight the vasculature has been examined in a
number of tumours (Kuzu et al, 1992; Toi et al, 1993), and the final
aim ofour study was to compare the microvessel staining abilities of
these commonly used endothelial cell markers in ovarian tumours.
MATERIALS AND METHODS
Tissue specimens
Specimens from benign, malignant and borderline primary ovarian
tumours were assessed. Only one block from each tumour was
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Table 1 Clinical information for subjects included in this study
Histological n Age (years) Clinical stage Patient outcome
type Mean (range)
I II IlIl IV Deceased Recurred Clear
Malignant
Serous 16 63 (48-78) 0 1 14 1 9 4 3
Mucinous 4 59 (41-74) 3 0 1 0 2 0 2
Borderline
Serous 5 45(29-55) 4 1 0 0 1 0 4
Mucinous 12 56 (34-87) 10 0 2 0 1 1 10
Benign 54 (23-85)
Cystadenoma 9 - - - - - - -
Other 10
available for microvessel quantification. The histopathology of
each tumour was confirmed before inclusion in the study. Blocks
lacking tumour components or microvessel immunostaining were
excluded from the study. A breakdown of the 19 benign and 37
borderline and malignant tumours included in the study and rele-
vant patient characteristics are presented in Table 1. Preliminary
follow-up information was collected up to 3 years (average of
21 months) after initial surgery. Staging of the malignant tumours
was performed according to International Federation of
Gynaecologists and Obstetricians guidelines. Ethical approval for
this study was obtained from the Monash Medical Centre
Research and Human Ethics Committee.
Immunohistochemistry
Specimens were fixed in buffered formalin and embedded in
paraffin. Serial sections were immunostained using antibodies to
the endothelial cell markers CD31 (mouse monoclonal JC/70A;
Dako, Botany, NSW, Australia; 1:50), CD34 (mouse monoclonal
QBend/10; Serotec, Australian Laboratory Services, Melbourne,
Victoria, Australia; 1:40) and factor VIII-related antigen (FVIII-
RA) (rabbit polyclonal; Behring, Behring Diagnostics, La Jolla,
CA, USA; 1:400). A positive control slide known to exhibit
endothelial cell staining with all three markers was included in
each staining run. A negative control slide, in which the primary
antibody was replaced by the same concentration of the appro-
priate mouse IgG (CD31 and CD34) or normal rabbit serum
(FVIII-RA), was also included in each staining run. Paraffin-
embedded serial sections (5 ,um) were mounted on 3-aminopropyl-
triethoxysilane (Sigma, Castle Hill, NSW, Australia)-coated
slides, dewaxed and rehydrated. Sections stained using CD31 anti-
body were predigested for 40 min at 37°C with 1 mg ml-' pepsin
(Sigma) in 3% acetic acid. Before incubation with the primary
antibody, all sections were quenched for 10 min with 3% hydrogen
peroxide in methanol. Non-specific binding of CD31 and CD34
antibody was blocked with a 20-min incubation in 10% normal
rabbit serum. Primary antibody was diluted in 1% bovine serum
albumin (CD31 and CD34) or 10% fetal calf serum (FVIII-RA)
in phosphate-buffered saline (PBS). CD31-immmunostained
sections were incubated overnight at room temperature, CD34-
stained sections for 45 min at 37°C and FVIII-RA-stained sections
for 60 min at 37°C. Following washing with PBS, sections were
incubated with an appropriate biotinylated secondary antibody
(Zymed, Bioscientific, Melbourne, Victoria, Australia), washed
with PBS again and incubated with horseradish peroxidase-
conjugated streptavidin (Zymed). After washing with PBS, the
colour was developed by incubating the sections with 3-amino-9-
ethylcarbazole (Zymed) for 10 min. Sections were then washed
with water, counterstained with haematoxylin and mounted with
Clearmount (Zymed) mounting medium.
Microvessel quantification
Sections were analysed using a Zeiss Axioskop microscope, and
the images projected to a Sony PVM1440QM video monitor using
a Sony CCDIRIS video camera. A preliminary examination ofthe
slides indicated that CD31 antibody gave the most sensitive and
specific staining ofendothelial cells. In contrast, stromal elements
of some tumours were CD34 positive and FVIII-RA antibody
appeared to stain fewer microvessels. Therefore sections stained
for CD31 were used to select HVD and AVD regions. The sections
were scanned at low power to locate regions of high MVD and
counts were obtained for these regions (100 x magnification,
0.29 mm2 field size). The region with the highest microvessel
count was selected and its location within the section noted. The
average vessel density region was selected by scanning the section
(100 x magnification) and obtaining microvessel counts for up to
20 fields. The average number of vessels per field was calculated
and a region representative of this average was selected. Vessels
were defined as any positively stained single cell or cluster of
cells. The presence of a lumen was not a defining characteristic.
The same region on serial sections stained for CD34 and FVIII-
RA was located and microvessel counts obtained. Vessel counts
per field were converted to vessels mm-2.
Statistics
All statistics were performed using the SPSS statistics package
(V6.1.2; SPSS Australasia, North Sydney, NSW, Australia).
Vessel density measurements were transformed to obtain homo-
geneity of variance if required and ANOVA conducted. Multiple
comparisons were performed using the Bonferroni t-procedure.
For single comparisons the data were transformed appropriately
and Student's t-test performed. The criterion of statistical signifi-
cance applied was P < 0.05.
RESULTS
Qualitative differences in blood vessel immunostaining
Vessel density within each tumour section was heterogeneous,
readily allowing HVD and AVD regions to be distinguished from
each other and from relatively avascular regions. This was evident
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Figure 1 Serial sections of a borderline serous tumour immunostained for CD31 (A), CD34 (B) and FVIII-RA (C). Fewer vessels (indicated by arrowheads) are
FVIII-RA positive. CD31-positive vessels in the high (D) and average (E) vessel density regions of a borderline mucinous tumour are shown. CD31-
immunostained section from a late stage serous tumour (F) showing both diffuse endothelial cell staining and staining localized to the endothelial cell boundary.
Scale bar indicates 50 ,um (x 400 magnification)
with all vessel markers tested in this study despite differences in
their endothelial cell staining ability (Figure 1). IgG and rabbit
serum negative control slides were clear of immunostaining.
Differences in the nature ofthe staining seen with each antibody
were apparent. CD34 staining was generally localized to
endothelial cells; however, stromal staining was observed in some
samples, particularly those from benign tumours. FVIII-RA
staining was frequently of a granular appearance. In some of the
more vascular malignant tumours and in the high vessel density
regions of some of the less vascular tumours CD31 appeared to be
localized to the endothelial cell boundary, giving the vessels a
striped appearance (Figure 1). This staining pattern was seen less
frequently in benign tumours. In other regions CD31 had a similar
diffuse endothelial cell staining pattern to that seen with CD34.
MVD in mucinous, serous and benign ovarian tumours
The mucinous and serous groups consisted of both borderline and
frankly malignant tumours of early and late stage. Analysis of
CD31 immunostaining indicated that MVD did not differ between
borderline and malignant mucinous tumours in both HVD
(238.3 ± 32.1; 204.8±30.1; t-test; P > 0.05) and AVD (81.9 ± 11.2;









Figure 2 Mean + s.e.m. vessels mm-2 determined using an antibody to
CD31 in high (empty bar) and in average (striped bar) vessel density regions
are shown. Tumour type is indicated below the chart. *Significantly greater
MVD was observed in mucinous relative to serous or benign tumours
(ANOVA; P < 0.001; d.f. = 2,53)
74.8 ± 17.4; t-test; P > 0.05) regions. In HVD regions MVD did
not differ (t-test; P > 0.05) between borderline (58.5 ± 12.2) and
malignant (120 ± 26.2) serous tumours. However in AVD regions
MVD in borderline tumours (12.9 ± 2.4) was significantly less
(t-test; P < 0.01) than that observed in malignant (40 ± 8.4)
tumours. For comparison of histological type, all mucinous
tumours and all serous tumours formed two groups. CD31
(Figure 2, Table 2) and CD34 (Table 2) immunostaining revealed
significantly greater MVD in both the HVD and AVD regions in
mucinous tumours compared with serous tumours and benign
tumours (ANOVA; P < 0.001; d.f. = 2, 53). Analysis of FVIII-RA
immunostaining revealed significantly greater MVD in the HVD
regions of mucinous relative to serous malignant tumours (Table
2; ANOVA; P < 0.05; d.f. = 2, 53). However, using this antibody,
MVD in AVD regions did not differ between histological types
(Table 2; ANOVA; P > 0.05). In both the HVD and AVD regions,
MVD, indicated by any of the three endothelial cell markers, did
not differ between malignant serous and benign tumours (Table 2;
ANOVA; P > 0.05).
Figure 3 Mean + s.e.m. vessels mm-2 determined using an antibody to
CD31 in high (empty bar) and in average (striped bar) vessel density regions
are shown. Tumour stage and type are indicated below the chart.
*Significantly greater MVD was observed in early-stage mucinous relative to
early- and late-stage serous tumours (ANOVA; P < 0.001; d.f. = 2,53)
MVD in early- and late-stage ovarian tumours
For comparisons based on tumour stage the histological subtypes
remained separate. However, the borderline and malignant groups
were combined. Both CD31 (Figure 3, Table 2) and CD34 (Table 2)
immunostaining demonstrated significantly greater MVD in
the HVD and AVD regions of early-stage mucinous tumours
compared with both early- and late-stage serous tumours (ANOVA;
P < 0.001; d.f. = 2, 31). MVD did not differbetween early- and late-
stage serous tumours (P > 0.05). FVIII-RA immunostaining in
HVD regions was significantly greater in early-stage mucinous than
late-stage serous tumours (Table 2; ANOVA; P < 0.05; d.f. = 2, 31).
However, similarly to the comparison ofhistological type, AVD did
not differ between tumour stage when evaluated using FVIII-RA
antibody (Table 2; ANOVA, P > 0.05; d.f. = 2, 31).
MVD and patient outcome
Most of the patients diagnosed with mucinous tumours remain
clear ofdisease, allowing analysis ofpatient outcome and MVD to
Table 2 Microvessel density in high (HVD) and average (AVD) vessel density regions,assessed using three endothelial cell markers
Endothelial cell marker
Tumour type CD1 CD34 FVIII-RA
HVD AVD HVD AVD HVD AVD
Mucinous
All 222.4 + 24.8 79.9 + 8.5 236.3 ± 28.2 103.0 ± 11.9 68.0 ± 17.3b 28.9 ± 6.8b
Stages l-ll 234.6 ± 28.2 87.8 ± 9.2 250.2 ± 32 112.9 ± 12.9 75.1 ± 20.4b 28.2 ± 8.2b
Serous
All 105.4 ± 20.7 33.3 ± 6.8 85.3 ± 22.4 42.8 ± 8.8 28.9 ± 7.1a 11.6 ± 2.4
Stages l-ll 72.8 ± 15 12.9 ± 2.4 36.0 ± 14.6 19.7 ± 5.4 23.8 ± 8.8a 12.9 ± 5.4b
Stages III-IV 115.6 ± 26.5 29.8 ± 8.5 100.6 ± 27.9 50 ± 10.9 30.3 ± 8.5* 11.2 ± 2.4*
Benign 84.4 ± 19.4 20.4 ± 4.4 83.3 ± 23.5 36.0 ± 7.8 40.5 ± 10.9 21.4 ± 3.7
MVD given as vessels mm-2 (mean ± s.e.m.). aFVIII-RA immunostaining is significantly less than that seen with DC31 and CD 34 (ANOVA;
P< 0.02);b FVIII-RA immunostaining is significantly less than that seen with CD31 (ANOVA; P< 0.001).
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Figure 4 Mean + s.e.m. vessel mm-2 de
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In the HVD and AVD regions of l
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DISCUSSION
In this study, we examined MVD i]
of ovarian tumours and observed
mucinous tumours relative to botl
Increased MVD in mucinous tum(
ously (Gasparini et al, 1996); how(
mucinous tumours were late-stage
MVD observed was thought to be a,
nosis of this tumour type relative to
current study, however, most of the
stage borderline tumours, a group w
observation of increased MVD in
frankly malignant and borderline se
dict the putative association betwe
prognosis in ovarian carcinoma
Gasparini et al, 1996).
The genetic profiles of malignant
serous tumour differ. Mutation of
shown to up-regulate expression of
'. endothelial growth factor (Rak et al, 1995b). Although mutation of
this gene is frequently observed in mucinous tumours, it rarely
occurs in serous ovarian tumours (Fujita et al, 1994). In contrast,
mutation of the tumour-suppressor gene p53 is more frequently
observed in serous ovarian tumours (Fujita et al, 1994) and may be
associated with down-regulation of the angiogenesis inhibitor
thrombospondin- I (Dameron et al, 1994). These observations
; ~ suggest that mucinous and serous ovarian tumours are character-
ized by different angiogenic pathways. Furthermore, mucinous
tumours are generally larger than malignant serous tumours (Hart,
_ -- . . - 1992), a factor that may also be associated with the increased
MVD observed in this tumour type.
When compared by tumour stage, early-stage mucinous
tumours exhibited higher MVD relative to both early- and late-
stage serous tumours. Because of the small group size, late-stage
mucinous tumours were excluded from this section of the study.
OISSI S <*Despite the poorprognosis oflate-stage compared withearly-stage
tt=4 h - e=7 serous tumours, no difference in MVD between the two groups
termined using an antibody to CD31 was observed. Previous studies of MVD in ovarian tumours have
,d bar) vessel density regions are not compared early- and late-stage serous tumours. A recent study
ndicate vessel densities in samples it. MVD did notdifferwith patient of angiogenic growth factor expression in ovarian tumours did
not demonstrate any association between pathological stage and
expression of platelet-derived endothelial cell growth factor
(Reynolds et al, 1994). Although the aggressiveness and pattern of
;erous group only. MVD evalu- spread ofearly- and late-stage serous tumours differs, their angio-
and FVIII-RA (data not shown) genic capacity appears to be similar. Patients diagnosed with early-
ither the HVD or AVD regions, stage mucinous tumours have a good prognosis, and the
-lear of disease, with recurrent observation of increased MVD in this group casts further doubt on
VA; P > 0.05; d.f. = 2, 20). the putative association between increased MVD and poor prog-
nosis in ovarian tumours.
id FVIII-RA Comparison of MVD in serous tumour samples from patients
with different outcomes did not reveal any differences in MVD.
mucinous tumours antibody to Previous studies examining MVD in ovarian carcinoma have used
ler microvessels than antibody survival curves to assess the prognostic ability of MVD, and two
< 0.0001; Table 2). In serous of these three studies demonstrated an association between higher
ipared with CD31 immuno- MVD and reduced survival (Hollingsworth et al, 1995; van Diest
-stage tumours (ANOVA; P < et al, 1995; Gasparini et al, 1996). Small group numbers and
FVIII-RA immunostaining in shorter follow-up times precluded the use of this technique in the
tly different from that obtained current study. As an alternative, we compared MVD in serous
(ANOVA; P> 0.05; Table 2). tumour samples from deceased patients, those with ongoing
disease and those clear ofdisease and in tumour types with known
differences in prognosis. The lack of observed difference between
serous tumours with different outcomes may be due to the inclu-
n both HVD and AVD regions sion of early-stage tumours and the short follow-up times relative
significantly greater MVD in to previous studies. It is possible that the use of MVD as a prog-
h serous and benign tumours. nostic indicator in ovarian tumours is only applicable to late-stage
ours has been reported previ- tumours, a group in which haematogenous spread may occur
ever, in this study most of the (Kristensen and Trope, 1997). In the previous studies of MVD in
e tumours, and the increased ovarian tumours, in which an association between increased MVD
ssociated with the poorer prog- and reduced survival has been demonstrated (Gasparini et al,
other histological types. In the 1996; Hollingsworth et al, 1995), most of the tumours have been
mucinous tumours were early- of the late-stage serous type.
ith a good prognosis. Thus, the In the current study MVD in benign ovarian tumours was similar
mucinous tumours relative to to that seen in malignant serous tumours, suggesting that a similar
rous tumours seems to contra- level of angiogenesis is occurring in these two tumour groups.
-en increased MVD and poor Microvessel density in benign ovarian tumours has not been exam-
(Hollingsworth et al, 1995; ined previously; however, these tumours can attain quite large sizes
(Deligdisch, 1994) and would be expected to induce an angiogenic
t and borderline mucinous and response to accommodate this growth. Expression of both VEGF
the oncogene K-ras has been and PDECGF has been demonstrated in benign ovarian tumours
the angiogenic factor vascular (Reynolds et al, 1994). Parallels between tumour angiogenesis,
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tumour invasion and metastasis have been suggested (Liotta et al,
1991; Rak et al, 1995a) and in some tumours the same mechanism
is thought to govern these processes. However, the similarity
between MVD in benign tumours and malignant serous tumours,
the higher MVD demonstrated in borderline mucinous tumours and
the similar MVD observed in early- and late-stage serous tumours
suggests that in ovarian tumours angiogenesis and tumour invasive-
ness and spread are not associated.
Differences in MVD between tumour groups were observed in
both the HVD and AVD regions. Most studies of MVD and prog-
nosis determine microvessel counts only in regions of HVD and
incorporating regions of AVD and low vessel density is thought to
reduce the value of MVD as a prognostic indicator (Rak et al,
1995a). Increased tumour cell shedding into the circulation is
associated with increased tumour vascularization (Liotta et al,
1974; McCulloch et al, 1995) and the importance of the vascular
'hot spot' relates to its role as the likely site of tumour cell entry
into the circulation and as an area of ongoing angiogenesis (Rak
et al, 1995a; Weidner, 1995). However, ovarian tumours rarely
spread via the vasculature and the observation of greater MVD in
both HVD and AVD regions of mucinous tumours suggests that
angiogenesis is occurring throughout the ovarian tumour vascula-
ture and may play a role in ongoing tumour growth rather than
metastatic spread.
In this study antibodies to CD31 and CD34 highlighted similar
numbers of microvessels. CD34 positivity of stromal elements has
been reported previously (Chaubal et al, 1994) and in the current
study was particularly apparent in benign ovarian tumours. Other
studies have reported CD31 positivity of tumour cells and plasma
(Chaubal et al, 1994; Weidner, 1995); however, we observed this
phenomenon only occasionally. In this study, the JC70 antibody to
CD31 was the most sensitive and specific markerofendothelial cells.
In both the mucinous and serous tumour groups examined in
this study, blood vessel immunostaining using an antibody to
FVIII-RA was significantly reduced relative to that seen with the
other endothelial cell markers. Reduced blood vessel immuno-
staining using antibodies to FVIII-RA has been observed in a
number oftumours (Toi et al, 1993; Hollingsworth et al, 1995) and
is thought to be due to the reduced expression of FVIII-RA in
smaller, less mature blood vessels (Schlingemann et al, 1991;
Visscher et al, 1994). The observation ofreduced immunostaining
in both the HVD and AVD regions of these tumours suggests that
both regions contain populations of larger, mature blood vessels
and smaller, less mature blood vessels, lending further support to
the hypothesis that angiogenesis is occurring throughout the
malignant and borderline ovarian tumour vasculature. It is note-
worthy that, although FVIII-RA immunostaining was reduced in
HVD regions of benign tumours, it was not to the level seen in
borderline and malignant tumours and was not observed at all in
AVD regions. It appears that the relative numbers of mature and
immature vessels in benign tumours differ from those seen in
borderline and malignant ovarian tumours. This finding and the
observation of increased MVD in early-stage mucinous tumours
may indicate that the level and control of angiogenesis differ
between ovarian tumour types.
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